Quilizumab

Quilizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IGHE
Clinical data
ATC code	none;
Identifiers
CAS Number	1228538-47-3;
ChemSpider	none;
UNII	26F96HRJ3W;
KEGG	D10409;
Chemical and physical data
Formula	C6492H10046N1728O2023S44
Molar mass	146082.49 g·mol−1

Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.[1] It binds to IGHE.[2][3][4][5][6][7]

This drug was developed by Genentech.

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Quilizumab, American Medical Association.
World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, Staubach P, Metz M, Sussman G, Maurer M (December 2016). "A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria". J. Allergy Clin. Immunol. 138 (6): 1730–1732. doi:10.1016/j.jaci.2016.06.023. PMID 27567329.
Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG (March 2016). "A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma". Respir. Res. 17: 29. doi:10.1186/s12931-016-0347-2. PMC 4797126. PMID 26993628.
Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM (July 2014). "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production". Sci Transl Med. 6 (243): 243ra85. doi:10.1126/scitranslmed.3008961. PMID 24990880. S2CID 41593528.
Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL (March 2017). "An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases". Curr Respir Med Rev. 13 (1): 22–29. doi:10.2174/1573398X13666170616110738. PMC 5735517. PMID 29290750.
Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB (2018). "Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria". J Allergy Clin Immunol Pract. 6 (4): 1108–1117. doi:10.1016/j.jaip.2018.02.024. PMID 30033912. S2CID 51710078.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Quilizumab, American Medical Association.

[2] World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).

[3] Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, Staubach P, Metz M, Sussman G, Maurer M (December 2016). "A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria". J. Allergy Clin. Immunol. 138 (6): 1730–1732. doi:10.1016/j.jaci.2016.06.023. PMID 27567329.

[4] Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG (March 2016). "A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma". Respir. Res. 17: 29. doi:10.1186/s12931-016-0347-2. PMC 4797126. PMID 26993628.

[5] Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM (July 2014). "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production". Sci Transl Med. 6 (243): 243ra85. doi:10.1126/scitranslmed.3008961. PMID 24990880. S2CID 41593528.

[6] Licari A, Castagnoli R, Panfili E, Marseglia A, Brambilla I, Marseglia GL (March 2017). "An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases". Curr Respir Med Rev. 13 (1): 22–29. doi:10.2174/1573398X13666170616110738. PMC 5735517. PMID 29290750.

[7] Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB (2018). "Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria". J Allergy Clin Immunol Pract. 6 (4): 1108–1117. doi:10.1016/j.jaip.2018.02.024. PMID 30033912. S2CID 51710078.